BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/23/2024 12:52:12 PM | Browse: 80 | Download: 219
 |
Received |
|
2023-12-25 15:56 |
|
Peer-Review Started |
|
2023-12-25 15:56 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-04-08 06:09 |
|
Revised |
|
2024-04-08 20:29 |
|
Second Decision |
|
2024-04-28 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-04-28 08:29 |
|
Articles in Press |
|
2024-04-28 08:29 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-14 08:20 |
|
Publish the Manuscript Online |
|
2024-05-23 12:52 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sunetra Mondal, Subhodip Pramanik, Vibhu Ranjan Khare, Cornelius James Fernandez and Joseph M Pappachan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, FRCP, MD, Academic Editor, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
SGLT2 inhibitors; SGLT2i; Cardiovascular disease; Heart failure; Atherosclerotic cardiovascular disease; Diabetic kidney disease |
| Core Tip |
The new antidiabetic medication class sodium glucose cotransporter-2 inhibitors (SGLT-2i) were found to have remarkable cardiovascular (CV) benefits proven by multiple randomised controlled trials and real-world observational studies. They are also useful in prevention of CV disease (CVD) in patients with diabetes mellitus. The CV benefits of SGLT-2i are not just because of antidiabetic effects. The preventive and management effects of SGLT2i molecules in diabetic and nondiabetic renal disease also translate into CV benefits. This clinical update review compiles the up-to-date evidence on the molecular mechanisms of SGLT-2i in prevention and management of CVD for empowering clinicians to rationalise the use of these molecules in day-to-day medical practice. |
| Publish Date |
2024-05-23 12:52 |
| Citation |
<p>Mondal S, Pramanik S, Khare VR, Fernandez CJ, Pappachan JM. Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives. <i>World J Cardiol</i> 2024; 16(5): 240-259</p> |
| URL |
https://www.wjgnet.com/1949-8462/full/v16/i5/240.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v16.i5.240 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
